Arthritis and pain - Future targets to control osteoarthritis pain

被引:98
作者
Dray, Andy
Read, Simon J.
机构
[1] AstraZeneca R&D, Montreal, PQ H4S 1Z9, Canada
[2] AstraZeneca R&D Mereside, Macclesfield SK10 4TG, Cheshire, England
关键词
D O I
10.1186/ar2178
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain pathways. This review focuses on symptomatic pain therapy exemplified by molecular targets that alter sensitization and hyperexcitability of the nervous system, for example, opioids and cannabinoids. We highlight opportunities for targeting inflammatory mediators and their key receptors (for example, prostanoids, kinins, cytokines and chemokines), ion channels (for example, NaV1.8, NaV1.7 and CaV2.2) and neurotrophins (for example, nerve growth factor), noting evidence that relates to their participation in OA etiology and treatment. Future neurological treatments of pain appear optimistic but will require the systematic evaluation of emerging opportunities.
引用
收藏
页数:14
相关论文
共 175 条
[21]   Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms [J].
Chang, Leon ;
Luo, Lin ;
Palmer, James A. ;
Sutton, Steven ;
Wilson, Sandy J. ;
Barbier, Ann J. ;
Breitenbucher, James Guy ;
Chaplan, Sandra R. ;
Webb, Michael .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (01) :102-113
[22]   Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain [J].
Chaplan, SR ;
Guo, HQ ;
Lee, DH ;
Luo, L ;
Liu, CL ;
Kuei, C ;
Velumian, AA ;
Butler, MP ;
Brown, SM ;
Dubin, AE .
JOURNAL OF NEUROSCIENCE, 2003, 23 (04) :1169-1178
[23]   Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain [J].
Chessell, IP ;
Hatcher, JP ;
Bountra, C ;
Michel, AD ;
Hughes, JP ;
Green, P ;
Egerton, J ;
Murfin, M ;
Richardson, J ;
Peck, WL ;
Grahames, CBA ;
Casula, MA ;
Yiangou, Y ;
Birch, R ;
Anand, P ;
Buell, GN .
PAIN, 2005, 114 (03) :386-396
[24]   L-acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors [J].
Chiechio, S ;
Caricasole, A ;
Barletta, E ;
Storto, M ;
Catania, MV ;
Copani, A ;
Vertechy, M ;
Nicolai, R ;
Calvani, M ;
Melchiorri, D ;
Nicoletti, F .
MOLECULAR PHARMACOLOGY, 2002, 61 (05) :989-996
[25]  
CHIZH B, 2006, J PAIN, V7, pS42
[26]   Antinociceptive synergy between Δ9-tetrahydrocannabinol and opioids after oral administration [J].
Cichewicz, DL ;
McCarthy, EA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (03) :1010-1015
[27]   Gait analysis in a rat model of osteoarthrosis [J].
Clarke, KA ;
Heitmeyer, SA ;
Smith, AG ;
Taiwo, YO .
PHYSIOLOGY & BEHAVIOR, 1997, 62 (05) :951-954
[28]   Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model [J].
Claveau, D ;
Sirinyan, M ;
Guay, J ;
Gordon, R ;
Chan, CC ;
Bureau, Y ;
Riendeau, D ;
Mancini, JA .
JOURNAL OF IMMUNOLOGY, 2003, 170 (09) :4738-4744
[29]   Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA [J].
Colquhoun, A ;
Lawrance, GM ;
Shamovsky, IL ;
Riopelle, RJ ;
Ross, GM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (02) :505-511
[30]   BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain [J].
Coull, JAM ;
Beggs, S ;
Boudreau, D ;
Boivin, D ;
Tsuda, M ;
Inoue, K ;
Gravel, C ;
Salter, MW ;
De Koninck, Y .
NATURE, 2005, 438 (7070) :1017-1021